Navigation Links
Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Date:11/27/2012

CAMBRIDGE, Mass., Nov. 27, 2012 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented  at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

MM-302 is a nanotherapeutic encapsulation of doxorubicin with anti-HER2 antibody fragments attached to its surface. MM-302 specifically targets cancer cells that overexpress the ErbB2 (HER2) receptor, releasing doxorubicin within the cell and limiting uptake into normal cells. 

"Merrimack believes MM-302 has the potential to achieve better efficacy than current standards of care and lessened risk of cardiac toxicity relative to free doxorubicin," said Ulrik B. Nielsen, Co-Founder and Chief Scientific Officer, Merrimack Pharmaceuticals. "We look forward to presenting both MM-302 Phase I data and preclinical research on its accompanying PET/CT imaging agent, MM-DX-929 at the upcoming Symposium."

Poster Overview:

  • A Phase 1 Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-positive (HER2+) Breast Cancer (Abstract #: P5-18-09)
    • Poster Session 5: Treatment - HER2-Targeted Therapy
      • Friday, December 7, 2012
      • 5:00 - 7:00 p.m. CT, Exhibit Hall A-B
  • A Novel 64Cu-Liposomal PET Agent (MM-DX-929) Predicts Response to Liposomal Chemotherapeutics in Preclinical Breast Cancer Models (Abstract #: P4-02-05)
    • Poster Session 4: Detection/Diagnosis - Molecular, Functional and Novel Imaging
      • Friday, December 7, 2012
      • 7:00 - 9:00 a.m. CT, Exhibit Hall A-B
  • Quantification of HER2 Expression at the Single Cell Level and HER2 Intratumoral Heterogeneity of Breast Cancer Tissue Samples Using Automated Image Analysis (Abstract #: P1-07-03)
    • Poster Session 1: Prognostic and Predictive Factors – Biomarkers, Methods
      • Wednesday, December 5, 2012
      • 5:00 – 7:00 p.m. CT, Exhibit Hall A-B

About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
2. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
3. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
4. Edison Pharmaceuticals Closes $20M Series F Financing
5. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
6. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
8. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
9. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
10. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
11. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is ... to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one of the ... annual award that was started in 2003 to salute young achievers in Southwest Florida ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... SABRE is ... run from September 11 to the end of November. , The Chicago, Illinois, based ... their community and teach them about the ease of taking their personal safety into ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a ... public health departments have been awarded five-year accreditation status through the Public ... of being served by a PHAB-accredited health department now extend to more ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition ... try taking a more holistic approach and use natural alternatives for all house ... collection is certified USDA guaranteeing that, the new line of essential oils, are ...
Breaking Medicine News(10 mins):